T. Rowe Price Investment Management, Inc. Immatics N.V. Call Options Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMTX
# of Institutions
74Shares Held
93.6MCall Options Held
158KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY12MShares$125 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY10.2MShares$106 Million0.55% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$97.8 Million2.22% of portfolio
-
Rtw Investments, LP New York, NY6.97MShares$72.6 Million0.58% of portfolio
-
Vestal Point Capital, LP New York, NY6.25MShares$65.1 Million1.77% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $794M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...